Literature DB >> 1005743

Thromboxane A2 and prostaglandin H2: potent stimulators of the swine coronary artery.

J Svensson, M Hamberg.   

Abstract

Thromboxane A2 was generated by incubation of arachidonic acid with a suspension of human platelets. The filtrate contained 266 +/- 46 ng/ml (n=10) of thromboxane A2 and 25 ng/ml or less of prostaglandin endoperoxides (prostaglandins G2+H2). Thromboxane A2 was 2-10 times more potent than prostaglandin H2 and 9-102 times and 26-308 times more potent than prostaglandins E2 and F2alpha, respectively, in causing contractions of the superfused swine coronary artery.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1005743     DOI: 10.1016/0090-6980(76)90128-3

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  6 in total

Review 1.  The prostanoids in hemostasis and thrombosis: a review.

Authors:  J B Smith
Journal:  Am J Pathol       Date:  1980-06       Impact factor: 4.307

2.  Stimulating effect of thromboxane B2 on isolated rat atria.

Authors:  L Sterin-Borda; L Canga; A L Gimeno
Journal:  Experientia       Date:  1981-06

3.  Release of 15-keto-13, 14-dihydro-thromboxane B2 and prostaglandin D2 during anaphylaxis as measured by radioimmunoassay.

Authors:  H Anhut; B A Peskar; W Bernauer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-12       Impact factor: 3.000

4.  Coronary vasodilator activity of 13,14-dehydroprostacyclin methyl ester: comparison with prostacyclin and other prostanoids.

Authors:  A L Hyman; P J Kadowitz; W E Lands; C G Crawford; J Fried; J Barton
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

5.  A regimen for low-dose aspirin?

Authors:  S P Hanley; J Bevan; S R Cockbill; S Heptinstall
Journal:  Br Med J (Clin Res Ed)       Date:  1982-11-06

6.  Role of thromboxane and prostacyclin in pulmonary vasomotor changes after endotoxin in dogs.

Authors:  C A Hales; L Sonne; M Peterson; D Kong; M Miller; W D Watkins
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.